Magtein® (Nutraceutical)

About Neurocentria

Neurocentria is a private, late-stage biotech pioneering a new class of therapies based on the novel mechanism of elevating intracellular magnesium at synapses to promote synaptogenesis and enhance synaptic function. Its lead drug candidate, NRCT-101SR, is in Phase 2b/3 trials for ADHD, depression, and Alzheimer's disease, with early clinical data showing rapid mood improvement and cognitive benefits. The company also has a revenue-generating nutraceutical arm, Magtein®, which serves as a commercial foundation and proof-of-concept for its core science.

Therapeutic Areas